Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


19 mayo 2016

Drug-coated balloon is viable alternative to drug-eluting stent

Cardiovascular News

Results from the BIOLUX randomised control trial, which were presented at EuroPCR 2016, indicate that the Pantera Lux drug-coated balloon (Biotronik) is angiographically non-inferior to stenting with the latest-generation drug-eluting stents at six months for the treatment of in-stent restenosis. The study, according to a press release, is only one of a few randomised controlled trials to compare a latest generation coronary drug-eluting stent to drug-coated balloon in this indication.

18 mayo 2016

Major new study to investigate abbreviated DAPT in high bleeding risk patients

Cardiovascular News

At EuroPCR (17–20 May, Paris, France), a new global study that involves 4,300 patients from 34 countries was announced. The study, according to a press release, is set to shed light into the use of short duration dual antiplatelet therapy (DAPT) in patients following stenting procedures, with a particular focus on those with a high bleeding risk. The investigator-initiated MASTER DAPT (Management of patients post bioresorbable polymer stent implantation with an abbreviated DAPT regimen) study will be supported by an unrestricted grant from Terumo.

18 mayo 2016

St Jude Medical launches PressureWire X Guidewire in Europe

Cardiovascular News

St Jude Medical has announced CE mark approval and European launch of the PressureWire X Guidewire fractional flow reserve (FFR) Measurement System. Designed to identify the severity of narrowings in the coronary arteries of patients with coronary artery disease (CAD), FFR measurement allows for a more effective assessment of coronary lesions (blockages), resulting in more accurate diagnosis. The company will showcase the new PressureWire X guidewire technology at the EuroPCR 2016 meeting (17–20 May, Paris, France). The PressureWire X guidewire European launch will include a measured rollout to targeted countries throughout 2016.

18 mayo 2016

Edwards´ surgical heart valve innovations demonstrate positive patient benefits

Cardiovascular News

Edwards Lifesciences has announced positive clinical trial results on two of its advanced innovations in surgical heart valves for the treatment of people with aortic valve disease. Data from three studies—COMMENCE, TRANSFORM and FOUNDATION—were presented as part of the late-breaking sessions at the American Association for Thoracic Surgery’s (AATS) 96th annual meeting.

20 julio 2016

Study indicates signal for valve degeneration in TAVI patients by eight years

Cardiovascular News

Speaking at EuroPCR (17–20 May, Paris, France), Danny Dvir reported that there is a significant increase in valve degeneration between five and seven years after a transcatheter aortic valve implantation (TAVI) device is implanted. Although stressing that this was a “preliminary analysis” using early-generation devices and, therefore, “we must be cautious”, he estimated that, based on these findings, about half of patients who undergo TAVI may show early signs of valve degeneration within eight years of implantation.

19 julio 2016

Manta large bore vascular closure device now approved in Europe

Cardiovascular News

Essential Medical has received CE mark approval for Manta; its large bore vascular closure device. The device is a novel vascular closure device designed to close punctures ranging from 10F to 24F at femoral arterial access sites after cardiac catheterisation procedures such as transcatheter aortic valve implantation (TAVI) and balloon aortic valvuloplasty.

19 julio 2016

Moderate risk of upper gastrointestinal bleeding after TAVI

Cardiovascular News

A large cohort study, published in Catheterization and Cardiovascular Interventions, indicates that transcatheter aortic valve implantation (TAVI) is associated with an overall 2% risk of upper gastrointestinal bleeding. It also shows that patients who are on triple antithrombotic therapy have a 10-fold increased risk of upper gastrointestinal bleeding compared with patients not on triple antithrombotic therapy.

19 julio 2016

Safety and efficacy of Carillon mitral contour system confirmed

Cardiovascular News

According to a study published in Open Heart, treatment with the Carillon device (Cardiac Dimensions) significantly reduces annular dimensions and improved mitral regurgitation, heart failure symptoms, and functional capacity in patients with functional mitral regurgitation. These data, from the third multicentre study (TITAN II) of the system, confirm the safe and efficacy of the Carillon device.

14 julio 2016

Enrolment completed in US early feasibility study on tricuspid repair

Cardiovascular News

Mitralign has announced that enrolment in the first phrase of its SCOUT study, which is evaluating percutaneous tricuspid repair with the Trialign system in patients with functional tricuspid regurgitation, has been completed. The company has also revealed that it has recently received approval to expand the study and enrol an additional cohort of patients in the USA.

13 julio 2016

“Strikingly higher” survival rates with Sapien 3 at one year compared with older devices

Cardiovascular News

Overall one-year survival was over 85% for high-risk or inoperable patients who underwent transcatheter aortic valve implantation (TAVI) with Sapien 3 (Edwards Lifesciences), according to a study published in Circulation. An American Heart Association press release reports that this survival rate is “strikingly higher” compared to patient outcomes reported in studies that used older TAVI systems.

04 mayo 2016

Konica Minolta release updated Sonimage HS1 compact ultrasound

Cardiovascular News

Konica Minolta have introduced a new version of the Sonimage HS1 compact ultrasound system, which is designed to enable improved image quality, streamlined workflow and new cardiac functionality for the point-of-care ultrasound market.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.